MedTrace Logo

Immune Checkpoints in Predicting Response to Neoadjuvant Therapy in Rectal Cancer

NCT05457075 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 38

Last updated 2023-05-09

No results posted yet for this study

Summary

Colorectal cancer is the third most frequently diagnosed type of cancer in the world. Recent developments in the treatment of cancers suggest that immune checkpoint inhibitors will play an important role. Many studies have documented many types of soluble receptors and ligands that can be detected in plasma in cancer, and plasma levels of these molecules correlate with cancer severity. There is only one study in the literature evaluating the status of soluble immune control points in patients with rectal cancer. The aim of this study is to investigate the role of serum immune checkpoints before neoadjuvant therapy in predicting clinical response in patients with rectal cancer. In this way, it is aimed to show whether immune checkpoints are predictive markers that can predict response to neoadjuvant therapy in patients with stage II-III rectal cancer.

Conditions

Interventions

DIAGNOSTIC_TEST

Immune checkpoint measure

The measurement of soluble immune checkpoints of stage II-III rectal cancer before neoadjuvant treatment

Sponsors & Collaborators

  • Istanbul Training and Research Hospital

    lead OTHER_GOV

Principal Investigators

  • Ufuk Oguz Idiz, Assoc.Prof. · Istanbul Training and Reseach Hospital

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-01
Primary Completion
2022-12-01
Completion
2023-02-15

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05457075 on ClinicalTrials.gov